| Price | 10.25p on 12-12-2025 at 19:40:08 |
|---|---|
| Change | 0.00p 0% |
| Buy | 10.50p |
| Sell | 10.00p |
| Last Trade: | Sell 33,345.00 at 10.10p |
| Day's Volume: | 1,326,273 |
| Last Close: | 10.25p |
| Open: | 10.25p |
| ISIN: | GB00BYV81293 |
| Day's Range | 10.15p - 10.25p |
| 52wk Range: | 2.20p - 12.35p |
| Market Capitalisation: | £108.83m |
| VWAP: | 10.0389p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 33,345 | 10.10p | Ordinary |
16:27:29 - 12-Dec-25 |
| Sell* | 150,065 | 10.00p | Ordinary |
16:19:14 - 12-Dec-25 |
| Sell* | 36,624 | 10.10p | Ordinary |
16:11:32 - 12-Dec-25 |
| Buy* | 25,265 | 10.275p | Ordinary |
15:57:12 - 12-Dec-25 |
| Unknown* | 97,444 | 10.25p | Ordinary |
15:51:55 - 12-Dec-25 |
| Sell* | 14,933 | 10.125p | Ordinary |
15:45:21 - 12-Dec-25 |
| Sell* | 3,000 | 10.125p | Ordinary |
15:39:22 - 12-Dec-25 |
| Sell* | 2,952 | 10.0125p | Ordinary |
14:34:38 - 12-Dec-25 |
| Buy* | 28 | 10.50p | SI Trade |
14:17:24 - 12-Dec-25 |
| Buy* | 190 | 10.50p | SI Trade |
14:17:24 - 12-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Dec 2025 7:00 am | RNS-R | Shield Wins Gold at Titan Branding Awards |
| 3rd Dec 2025 7:04 am | RNS | Amends Senior Secured Debt Financing |
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |
